Abstract
Identification of reliable metabolic and physiological NMR detectable markers for prediction and early detection of therapeutic response is essential to enabling NMR guided individualized therapy for cancer. Because non-Hodgkin’s lymphoma (NHL) is a prevalent form of cancer that exhibits~50% response to therapy and often presents with large superficial lesions easily accessible to multinuclear magnetic resonance spectroscopy (MRS) measurements, it is an ideal test bed for development ofNMRmethods for prediction and early detection of response.Amulticenter study, in which we have participated, has already shown that pre-treatment31 PMRS measurement of the phosphate monoester (PME)to nucleoside triphosphate (NTP) ratio can identify about 2/3 of the patients who are destined not to exhibit a complete clinical response to a variety of therapeutic agents.Because 31PMRS is limited to relatively large superficial tumors, we have been exploring 1HMRS andMRI methods for early detection of therapeutic response. Using xenografts of the most common form of human NHL, diffuse large B-cell lymphoma (DLBCL), we have detected therapeutic response within one cycle of therapy with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), rituximab plus CHOP (RCHOP) or radiation (15 Gy) through detection of a decrease in lactic acid (Lac) or total choline (tCho) and an increase of apparent diffusion coefficients (ADC). We have also performed 1H MRS of NHL patients in a clinical scanner. One of the patients exhibited a 70% decrease in Lac within 48 h of treatment with RCHOP.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Arias-Mendoza F, Smith MR, Brown TR. (2004) Predicting treatment response in non- Hodgkin’s lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine. Acad Radiol 11:368-376.
Arias-Mendoza F, Payne GS, Zakian K et al (2008) Treatment response predictor using 31P MRS for CHOP and R-CHOP Therapy in Diffuse Large B-Cell Lymphoma. Proc Intl SocMag Reson Med 16:768.
Pickup S, Lee SC, Mancuso A et al (2008) Lactate imaging with Hadamard-encoded sliceselective multiple quantum coherence chemical-shift imaging. Magn Reson Med 60:299-305.
Lee SC, Huang MQ, Nelson DS et al (2008) In vivo MRS markers of response to chop chemotherapy in the WSU-DLCL2 human diffuse large B-cell lymphoma xenograft. NMR Biomed 21:723-733.
Bui T, Thompson CB. (2006) Cancer’s sweet tooth. Cancer Cell 9:419-420.
Lee SC, Delikatny EJ, Poptani H et al (2009) In vivo 1H MRS of WSU-DLCL2 human non-Hodgkin’s lymphoma xenografts: response to rituximab and rituximab plus CHOP. NMR Biomed 22:259-266.
Lee SC, Poptani H, Pickup S et al (2010) Early detection of radiation therapy response in non- Hodgkin’s lymphoma xenografts by in vivo 1H magnetic resonance spectroscopy and imaging. NMR Biomed 23:624-632.
Mellon EA, Lee SC, Pickup S et al (2009) Detection of lactate with a hadamard slice selected, selective multiple quantum coherence, chemical shift imaging sequence (HDMD-SelMQCCSI) on a clinicalMRI scanner: application to tumors and muscle ischemia. Magn Reson Med 62:1404-1413.
Warburg O. (1956) On the origin of cancer cells. Science 123:309-314.
Podo F. (1999) Tumour phospholipid metabolism. NMR Biomed 12:413-439.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this paper
Cite this paper
Lee, SC. et al. (2011). NMR Metabolic and Physiological Markers of Therapeutic Response. In: LaManna, J., Puchowicz, M., Xu, K., Harrison, D., Bruley, D. (eds) Oxygen Transport to Tissue XXXII. Advances in Experimental Medicine and Biology, vol 701. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-7756-4_18
Download citation
DOI: https://doi.org/10.1007/978-1-4419-7756-4_18
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-7755-7
Online ISBN: 978-1-4419-7756-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)